Inside the transformation that doubled revenue, redefined a category, and led to multiple premium acquisitions.
Book your Exit Readiness Diagnostic
Every great company starts with a conviction. For BioPlus Specialty Pharmacy, it began more than 30 years ago with Dr. Stephen Vogt, PharmD, standing at a patient’s bedside. His belief was simple: access to life-saving specialty medicines should be fast, easy, and compassionate.
That belief grew BioPlus into a respected independent pharmacy, but by 2017, despite $750M in revenue, BioPlus had a visibility problem. Many patients, providers, and even pharma partners simply didn’t know who they were. Competitors were consolidating. PBM giants were tightening their grip. BioPlus risked being invisible in a crowded, commoditized market.
Recognizing the opportunity to strengthen BioPlus’ market position, Dr. Vogt invited Mark Montgomery, a seasoned pharmacy executive known for scaling and selling Axium Healthcare Pharmacy to Kroger, to join as President. Working side by side, Dr. Vogt and Mark led BioPlus through a pivotal transformation, expanding the leadership team, unifying the brand, and positioning the company for sustainable growth and eventual acquisition.
Beyond the story, BioPlus needed a repeatable model for growth. Under Dr. Vogt’s continued leadership as CEO, with Mark Montgomery serving as President and Legacy DNA embedded as Fractional CMO and agency of record, BioPlus built a growth engine that delivered 13 consecutive quarters of growth.
Together, Dr. Vogt and Mark combined clinical excellence with strategic execution. They assembled a veteran leadership team, sharpened operational discipline, and aligned the company around a shared vision for scalable impact.
Key growth milestones included:
When Dr. Vogt retired, Mark continued the mission they had set in motion. He completed the transformation and ultimately led BioPlus to a premium acquisition.
That partnership with Legacy DNA began by uncovering what truly set BioPlus apart and turning it into a story the entire market could understand.
The result was the Power of 2™:
It seemed simple but it was transformative. The Power of 2 became a rallying cry across the company, aligning every employee, every touchpoint, and every conversation around a story that customers remembered, providers trusted, and buyers could not ignore.
“Roxie and her team helped us translate vision into velocity. They brought structure, story, and strategy that turned BioPlus into a company buyers could not ignore.” — Mark Montgomery, President, BioPlus Specialty Pharmacy
And most importantly:
Two premium exits. One unforgettable growth journey.
What makes a company irresistible is clarity, not size. A crisp, compelling story. A repeatable growth model. A market presence competitors cannot ignore and buyers fight to acquire.
That is the essence of Exit Readiness.
“We had something good. Legacy DNA made it better. And then some.” — Dr. Stephen Vogt, Founder and CEO, BioPlus Specialty Pharmacy
The same clarity, credibility, and disciplined growth that made these companies irresistible to buyers are the same fundamentals that determine your valuation.
If you’ve already completed your Exit Readiness Scorecard™, your next step is a private Exit Readiness Diagnostic.
In this 30-minute session, we’ll:
You’ll leave with a clearer picture of how buyers view your company and the exact steps to strengthen your position before your next funding round or acquisition process.
Book your Exit Readiness Diagnostic
If you’re ready to accelerate that transformation, explore the Exit Readiness Sprint™, a 90-day program that builds the personas, messaging, positioning, and corporate story that make buyers take notice.
